These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 2956871)

  • 21. Short-term effects of oral enoximone on hemodynamics, exercise capacity, anaerobic threshold, and arrhythmias in congestive heart failure.
    Klauss V; Zwehl W; Mudra H; Huber R; Schmidt R; Scheininger M; Vogler A; Tschaidse O; Dieterich HA; Theisen K
    Klin Wochenschr; 1991 Jul; 69(10):430-5. PubMed ID: 1719270
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MDL 17,043: short- and long-term cardiopulmonary and clinical effects in patients with heart failure.
    Rubin SA; Tabak L
    J Am Coll Cardiol; 1985 Jun; 5(6):1422-7. PubMed ID: 3158690
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Additive effects of enoximone and nitroprusside in unstable chronic heart failure.
    Treese N; Erbel R; Rhein S; Henrichs KJ; Meyer J
    Eur Heart J; 1989 Jun; 10(6):484-92. PubMed ID: 2527155
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Enoximone/dobutamine comparison in chronic congestive cardiac insufficiency with low cardiac output].
    Galinier M; Rochiccioli JP; Edouard P; Fourcade J; Massabuau P; Puel J; Fauvel JM; Bounhoure JP
    Arch Mal Coeur Vaiss; 1990 Sep; 83 Spec No 3():27-32. PubMed ID: 2147831
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rationale and design of the enoximone clinical trials program.
    Lowes BD; Shakar SF; Metra M; Feldman AM; Eichhorn E; Freytag JW; Gerber MJ; Liard JF; Hartman C; Gorczynski R; Evans G; Linseman JV; Stewart J; Robertson AD; Roecker EB; Demets DL; Bristow MR
    J Card Fail; 2005 Dec; 11(9):659-69. PubMed ID: 16360960
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Placebo-controlled trial of oral enoximone in end-stage congestive heart failure refractory to optimal treatment.
    Dubourg O; Delorme G; Hardy A; Beauchet A; Tarral A; Bourdarias JP
    Int J Cardiol; 1990 Jul; 28 Suppl 1():S33-42; discussion S43. PubMed ID: 2145237
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of enoximone on exercise tolerance in patients with mild to moderate heart failure.
    Itoh H; Taniguchi K; Doi M; Koike A; Sakuma A
    Am J Cardiol; 1991 Aug; 68(4):360-4. PubMed ID: 1830450
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acute effects of enoximone in chronic heart failure.
    Saborowski F; Peters P; Schneider M; Fehske W; Dieterich HA
    J Cardiovasc Pharmacol; 1989; 14 Suppl 1():S57-61. PubMed ID: 2480487
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acute and long-term hemodynamic response to low-dose enoximone in refractory heart failure.
    McDonald KM; O'Sullivan JJ; McWilliams EW; Conroy RC; Maurer BJ
    Cardiovasc Drugs Ther; 1989 Dec; 3(6):913-8. PubMed ID: 2535057
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Treatment of chronic cardiac insufficiency with intravenous bolus enoximone. Study of a pharmacokinetic-hemodynamic relation].
    Gibelin P; Garraffo R; Sbirrazzuoli V; Lapalus P; Morand P
    Arch Mal Coeur Vaiss; 1990 Sep; 83 Spec No 3():75-81. PubMed ID: 2147839
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A preliminary report of the effects of orally administered enoximone on regional hemodynamics in congestive heart failure.
    Leier CV; Meiler SE; Matthews S; Unverferth DV
    Am J Cardiol; 1987 Aug; 60(5):27C-30C. PubMed ID: 2956864
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intravenous use of enoximone.
    Crawford MH
    Am J Cardiol; 1987 Aug; 60(5):42C-45C. PubMed ID: 2956867
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enoximone. A review of its pharmacological properties and therapeutic potential.
    Vernon MW; Heel RC; Brogden RN
    Drugs; 1991 Dec; 42(6):997-1017. PubMed ID: 1724645
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Piroximone (MDL 19,205) in the treatment of unstable and stable chronic cardiac failure.
    Weber KT; Janicki JS; Jain MC
    Am Heart J; 1987 Oct; 114(4 Pt 1):805-13. PubMed ID: 3310566
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MDL 17,043 therapy in severe congestive heart failure: characterization of the early and late hemodynamic, pharmacokinetic, hormonal and clinical response.
    Uretsky BF; Generalovich T; Verbalis JG; Valdes AM; Reddy PS
    J Am Coll Cardiol; 1985 Jun; 5(6):1414-21. PubMed ID: 3158689
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Vasodilatation and positive inotropic effect of the phosphodiesterase inhibitor enoximone].
    Holubarsch C; Hasenfuss G; Thierfelder L; Heiss HW; Just H
    Z Kardiol; 1991; 80 Suppl 4():35-40. PubMed ID: 1833895
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative effects on hemodynamics of enoximone (MDL 17,043), dobutamine and nitroprusside in severe congestive heart failure.
    Installé E; Gonzalez M; Jacquemart JL; Collard P; Roulette F; Pourbaix S; Tremouroux J
    Am J Cardiol; 1987 Aug; 60(5):46C-52C. PubMed ID: 2956868
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Enoximone: hemodynamic effect in patients with cardiac insufficiency].
    de Langenhagen B; Bouchoucha H; Scholl JM; Hennetier G; Benacerraf A; Achard F; Bock F
    Arch Mal Coeur Vaiss; 1990 Sep; 83 Spec No 3():19-25. PubMed ID: 2147830
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Electrophysiologic effects of enoximone in patients with congestive heart failure.
    Hohnloser SH; Zehender M; Geibel A; Meinertz T; Just H
    J Cardiovasc Pharmacol; 1989; 14 Suppl 1():S29-32. PubMed ID: 2480482
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A double-blind dose response comparison of oral enoximone and placebo for congestive heart failure.
    Zipperle G; Butzer F; Dieterich HA; Heinrich F
    Am J Cardiol; 1987 Aug; 60(5):72C-74C. PubMed ID: 2956873
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.